الفهرس 
Impact of serum levels of interleukin-18 and soluble interleukin-2 receptor on the clinical outcome of patients with diffuse large b cell lymphoma treated with R-CHOP regimen
AbstractOnly 14 pages are availabe for public view
 |  | from | 184 |  |  |
| | | from | 184 | | |
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL in Egypt representing 53.8% of NHL cases according to Egypt National Cancer Registry. Since the introduction of rituximab, the utility of IPI in DLBCL patients treated in the rituximab era has been questioned. Instead, biologic prognostic factors including cytokines are increasingly investigated to stratify DLBCL patients. Several investigators reported that the knowledge of the serum levels of Interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in newly diagnosed DLBCLs may help us predict the clinical outcome of patients with aggressive non-Hodgkin{u2019}s lymphoma treated with R-CHOP. Methods: This study aimed to assess the impact of serum levels of of serum levels of IL-18 and sIL-2R on the clinical outcome of patients with DLBCL treated with R-CHOP protocol. During the period between November 2014 and November 2018, seventy-three patients with DLBCL were included. Results: Among the seventy-three patients included in the study, 44 patients (60%) were males and 29 patients (40%) were females. The median age at presentation was 53 years (range: 18-68 years). Elevation of serum IL-18 was associated with numerically lower CR, and 3-yr DFS rates, compared with lower serum levels group, however the difference was not statistically significant for both endpoints. Nevertheless, the 3-yr overall survival rates for patients with high and low serum IL-18 levels were significantly in favor of lower serum IL-18 level group. Correspondingly, the CR, 3-yr DFS, and OS rates for patients with low pretreatment sIL-2R levels were significantly better than individuals with higher levels